At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from Istituto Europeo di Oncologia, Milan, Italy, provides an overview of the challenges in the clinical development of precision medicine, which is defined as treatment selection that is guided by specific molecular aberrations in a patient’s tumour, for patients with breast cancer.
>